David Craig, PharmD, Named to FDA Advisory Committee

Get Permission

David Craig, PharmD

Moffitt Cancer Center recently announced that Clinical Pharmacist David Craig, PharmD, has been appointed to the U.S. Food and Drug Administration’s Anesthetic and Analgesic Drug Products Advisory Committee. Dr. Craig specializes in pain medicine and palliative care. The Anesthetic and Analgesic Drug Products Advisory Committee reviews and evaluates the safety and effectiveness of products used for anesthesiology as well as for treatment for pain after surgery. 

“Through my involvement on this committee, I hope to improve the safety and efficacy of all pharmacological analgesic treatment strategies,” said Dr. Craig. The committee consists of 13 members, who are knowledgeable in the fields of anesthesiology, surgery, epidemiology, and other related specialties.

Safe Tools to Manage Pain

 “My interest in pain management began when I was a pharmacist resident at Duke University Hospital and continued at Moffitt. I was intrigued when I first discovered that often simple clinical strategies can have such a significant impact on something patients cared so much about—their pain control. I am honored that as a member of the Anesthetic and Analgesic Drug Products Advisory Committee, I will guide policy that will impact patients directly and provide them with safe tools to manage their pain,” said Dr. Craig.

Dr. Craig has worked at Moffitt for over 10 years. During that time he became a member of the American Pain Society and served on the Board of Directors for 3 years and recently completed a 2-year term as Secretary of the society.  In addition, he recently completed the Mayday Pain and Society Fellowship, which educates physicians, nurses, pharmacists, social workers, scientists, and legal scholars in the pain management community to more effectively communicate their work and raise awareness about and improve the treatment of acute and chronic pain. His appointment to the Anesthetic and Analgesic Drug Products Advisory Committee will run through 2018. ■




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.